Edit
沙砾生物GRIT Biotechnology是一家聚焦世界尖端生物科技，专注于肿瘤免疫治疗领域的高科技创新企业。
https://www.grit-bio.com/Last activity: 10.07.2026
Active
Location: China, Shanghai
Employees: 51-200
Total raised: $60M
Founded date: 2019
Investors 2
| Date | Name | Website |
| 10.07.2026 | B Capital ... | b.capital/ |
| 11.07.2025 | B Capital ... | bcapgroup.... |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 08.09.2023 | Series B | $60M | - |
Mentions in press and media 9
| Date | Title | Description |
| 06.12.2025 | Vivacta Bio Announces Promising First-in-Human Results for GT801, an In Vivo CAR-T Therapy, in Non-Hodgkin's Lymphoma at the 2025 ASH Annual Meeting | SHANGHAI, Dec. 6, 2025 /PRNewswire/ -- Vivacta Bio, a spin-off company of Grit Biotherapeutics advancing in vivo CAR-T therapies for oncology and autoimmune diseases, today announced encouraging initial data from an investigator-initiated, ... |
| 04.11.2025 | Grit Biotherapeutics Invited to Deliver Oral Presentation at ASH 2025 on Breakthrough In Vivo CAR-T Therapy GT801 | BEIJING, Nov. 4, 2025 /PRNewswire/ -- Grit Biotherapeutics Co., Ltd. ("Grit Bio"), a leading clinical-stage biopharmaceutical company pioneering next-generation immunotherapies, today announced that its groundbreaking GT801 in viv... |
| 29.05.2025 | Grit Biotechnology Presents Clinical Breakthroughs at 2025 ASCO Annual Meeting | SHANGHAI, May 29, 2025 /PRNewswire/ -- Grit Biotechnology Co., Ltd. ("Grit Bio"), a clinical-stage biotech pioneering novel immunotherapies announced today that three abstracts featuring new clinical data from tumor-infiltrating l... |
| 12.05.2025 | Grit Biotechnology Presents Multiple Scientific Breakthroughs at ASGCT 2025 Annual Meeting | SHANGHAI, May 12, 2025 /PRNewswire/ -- Grit Biotechnology Co., Ltd. ("Grit Bio"), a clinical-stage biotech pioneering novel immunotherapies announced today that three research programs, in collaboration with Vitalgen BioPharma Co.... |
| 15.04.2025 | Vitalgen's Cutting-Edge Gene Editing and Delivery Platforms to be Featured at AACR Annual Meeting 2025 | Collaborative research with Grit Biotechnology showcases Vitalgen's proprietary platform and delivery systems in oncology applications These AACR presentations showcase how our proprietary platforms can enable breakthrough therapies across ... |
| 03.01.2025 | GRIT Bio Appoints Jie Jia, Ph.D., as Chief Operating Officer | SHENZHEN, China, Jan. 3, 2025 /PRNewswire/ -- Shenzhen GRIT Biotechnology Co., Ltd., a leading company in cell therapy globally, today announced the appointment of Jie Jia, Ph.D., as Chief Operating Officer (COO), effective on the date of t... |
| 08.09.2023 | Grit Biotechnology Announces Closing of $60 Million Series B Financing | SHANGHAI, Sept. 8, 2023 /PRNewswire/ -- On September 8, 2023, Grit Biotechnology announced the completion of a Series B financing round, raising over 60 million USD. The investment was led by CICC with participation from Qianhai Ark, Liando... |
| 08.09.2023 | Grit Biotechnology Closes $60M Series B Financing | Grit Biotechnology, a Shanghai, China-based cell therapy company, raised $60M in Series B funding. The round was led by CICC with participation from Qianhai Ark, Liando Group, Yuanhe Capital, HeFangTian Venture Partnership and existing inve... |
| - | GRIT Biotechnology | “Sandan Biopharmaceutical GRIT Biotechnology is a high-tech innovation enterprise focused on the field of immunotherapy for swelling and swelling.” |